[1] Nusrat S, Khan MS, Fazili J, et al. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol, 2014; 20, 5442−60. doi:  10.3748/wjg.v20.i18.5442
[2] D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006; 44, 217−31. doi:  10.1016/j.jhep.2005.10.013
[3] Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med, 2014; 12, 159. doi:  10.1186/s12916-014-0159-5
[4] Sain SK, Maiwall R. Global burden of liver disease: a true burden on health sciences and economies. http://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/global-burden-of-liver-disease-a-true-burden-on-health-sciences-and-economies. [2018-7-17].
[5] Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 2016; 388, 1603−58. doi:  10.1016/S0140-6736(16)31460-X
[6] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 2012; 380, 2095−128. doi:  10.1016/S0140-6736(12)61728-0
[7] Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 2012; 380, 2197−223. doi:  10.1016/S0140-6736(12)61689-4
[8] Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 2017; 390, 1211−59. doi:  10.1016/S0140-6736(17)32154-2
[9] Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 2017; 390, 1151−210. doi:  10.1016/S0140-6736(17)32152-9
[10] Hay SI, Abajobir AA, Abate KH, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 2017; 390, 1260−344. doi:  10.1016/S0140-6736(17)32130-X
[11] Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology, 2014; 60, 2099−108. doi:  10.1002/hep.27406
[12] Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med, 2014; 12, 145. doi:  10.1186/s12916-014-0145-y
[13] Wong MCS, Huang J. The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int, 2018; 12, 201−3. doi:  10.1007/s12072-018-9865-y
[14] Organization WH. Global hepatitis report, 2017. Available on https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. [2018-7-10]
[15] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet, 2015; 386, 1546−55. doi:  10.1016/S0140-6736(15)61412-X
[16] Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol, 2017; 2, 161−76.
[17] Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 2011; 17, 107−15. doi:  10.1111/j.1469-0691.2010.03432.x
[18] Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol, 2013; 59, 160−8. doi:  10.1016/j.jhep.2013.03.007
[19] Li YM, Fan JG, Wang BY, et al. Guidelines for the diagnosis and management of alcoholic liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18: 167-170). J Dig Dis, 2011; 12, 45−50. doi:  10.1111/j.1751-2980.2010.00477.x
[20] Wang H, Abajobir AA, Abate KH, et al. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 2017; 390, 1084−150. doi:  10.1016/S0140-6736(17)31833-0
[21] Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 2017; 390, 1345−422. doi:  10.1016/S0140-6736(17)32366-8
[22] Bai YM, Liu M, Chen B, et al. Analyzing retrospectively the important policies for chronic disease prevention and control in China during 1984 and 2014. Chinese Journal of Prevention Control of Chronic Diseases, 2016; 24, 563−7. (In Chinese)
[23] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet, 1997; 349, 825−32. doi:  10.1016/S0140-6736(96)07642-8
[24] Tommaso S, Rozenn E, Elisa B, et al. Gender differences in chronic HBsAg carriers in Italy: evidence for the independent role of male sex in severity of liver disease. J Med Virol , 2015; 87, 1899−903. doi:  10.1002/jmv.24243
[25] Wang WJ, Xiao P, Xu HQ, et al. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol, 2019; 25, 1445−56. doi:  10.3748/wjg.v25.i12.1445
[26] Zhang M, Wu R, Xu H, et al. Changing incidence of reported viral hepatitis in China from 2004 to 2016: an observational study. BMJ Open, 2019; 9, e028248. doi:  10.1136/bmjopen-2018-028248
[27] Cohen AK, Syme SL. Education: a missed opportunity for public health intervention. Am J Public Health, 2013; 103, 997−1001. doi:  10.2105/AJPH.2012.300993
[28] Wang B, Feng Y, Li Z, et al. Distribution and diversity of hepatitis B virus genotypes in Yunnan, China. J Med Virol, 2014; 86, 1675−82. doi:  10.1002/jmv.24002
[29] Cui Ya, Moriyama M, Rahman MM. Analysis of the incidence of hepatitis B and hepatitis C and association with socio-economic factors in various regions in China. Health, 2018; 10, 1210−20. doi:  10.4236/health.2018.109093
[30] Wang H, Ma L, Yin Q, et al. Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China. Alcohol Clin Exp Res, 2014; 38, 1035−41. doi:  10.1111/acer.12321
[31] Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol, 2013; 28, 11−7.
[32] Xia L. On the relationship between income and subjective well-being—based on the survey Data of Beijing city's floating population. Journal of Xihua University, 2014; 33, 101−7. (In Chinese)
[33] Gong T, Gong Y, Dong D. A cross-sectional study on hepatitis B in migrant workers of Chongqing. Modern Preventive Medicine, 2007; 20, 3842−4. (In Chinese)
[34] Yan YP, Su HX, Ji ZH, et al. Epidemiology of hepatitis B virus infection in China: current status and challenges. J Clin Transl Hepatol, 2014; 2, 15−22.
[35] Hu X, Zhang H, Sun X, et al. Older adults' choices of first-contact care and related factors in Zhejiang and Qinghai Province, China. Geriatr Gerontol Int, 2019; 19, 938−44. doi:  10.1111/ggi.13746
[36] He AJ. Introducing voluntary private health insurance in a mixed medical economy: are Hong Kong citizens willing to subscribe? BMC Health Serv Res, 2017; 17, 603. doi:  10.1186/s12913-017-2559-7
[37] Jia Y, Li L, Cui F, et al. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. Hum Vaccin Immunother, 2014; 10, 2983−91. doi:  10.4161/hv.29944
[38] Duan Z, Jia JD, Hou J, et al. Current challenges and the management of chronic hepatitis C in mainland China. J Clin Gastroenterol, 2014; 48, 679. doi:  10.1097/MCG.0000000000000109
[39] Stein E, Cruz-Lemini M, Altamirano J, et al. Heavy daily alcohol intake at the population level predicts the weight of alcohol in cirrhosis burden worldwide. J Hepatol, 2016; 65, 998−1005. doi:  10.1016/j.jhep.2016.06.018
[40] Tang YL, Xiang XJ, Wang XY, et al. Alcohol and alcohol-related harm in China: policy changes needed. Bull World Health Organ, 2013; 91, 270−6. doi:  10.2471/BLT.12.107318
[41] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64, 73−84. doi:  10.1002/hep.28431
[42] Chu YJ, Yang HI, Wu HC, et al. Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. Int J Cancer, 2017; 141, 711−20. doi:  10.1002/ijc.30782
[43] Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 2009; 286, 9−14. doi:  10.1016/j.canlet.2008.10.040
[44] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a China perspective. J Hepatol, 2019; 71, 212−21. doi:  10.1016/j.jhep.2019.03.004
[45] Man-Man W, Gong-Sui W, Feng S, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci, 2014; 59, 2571−9. doi:  10.1007/s10620-014-3180-9
[46] Pol S, Haour G, Fontaine H, et al. The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. Aliment Pharmacol Ther, 2017; 46, 1054−60. doi:  10.1111/apt.14352